RadNet unit DeepHealth wins FDA clearance for mammogram-based arterial calcification tool

RadNet, Inc.

RadNet, Inc.

RDNT

0.00
  • DeepHealth, a RadNet subsidiary, received two FDA 510(k) clearances expanding its AI breast imaging suite.
  • Clearances cover automated breast arterial calcification assessment on mammograms, adding cardiovascular risk insights to routine screening.
  • Also cleared prior-exam integration for ProFound Pro; the product will be marketed as Mammo Dx to help track lesions, improve detection, reduce recalls.
  • Both functionalities are commercially available in the US; BAC Assessment is slated for deployment across RadNet imaging centers.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. RadNet Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606250600PRIMZONEFULLFEED9752389) on June 25, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.